143 related articles for article (PubMed ID: 35962287)
21. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
22. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
[TBL] [Abstract][Full Text] [Related]
23. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
24. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
25. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
26. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
[TBL] [Abstract][Full Text] [Related]
27. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
28. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V; Barber-Rotenberg JS; Jung IY; Lacey SF; Rech AJ; Davis MM; Hwang WT; Lal P; Carpenter EL; Maude SL; Plesa G; Vapiwala N; Chew A; Moniak M; Sebro RA; Farwell MD; Marshall A; Gilmore J; Lledo L; Dengel K; Church SE; Hether TD; Xu J; Gohil M; Buckingham TH; Yee SS; Gonzalez VE; Kulikovskaya I; Chen F; Tian L; Tien K; Gladney W; Nobles CL; Raymond HE; ; Hexner EO; Siegel DL; Bushman FD; June CH; Fraietta JA; Haas NB
Nat Med; 2022 Apr; 28(4):724-734. PubMed ID: 35314843
[TBL] [Abstract][Full Text] [Related]
29. IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model.
Wang D; Shao Y; Zhang X; Lu G; Liu B
J Transl Med; 2020 Jan; 18(1):23. PubMed ID: 31937346
[TBL] [Abstract][Full Text] [Related]
30. CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy.
Tian Y; Wen C; Zhang Z; Liu Y; Li F; Zhao Q; Yao C; Ni K; Yang S; Zhang Y
Cancer Immunol Immunother; 2022 Nov; 71(11):2663-2675. PubMed ID: 35352167
[TBL] [Abstract][Full Text] [Related]
31. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
32. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
34. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
Sun R; Luo H; Su J; Di S; Zhou M; Shi B; Sun Y; Du G; Zhang H; Jiang H; Li Z
Mol Ther; 2021 Jan; 29(1):60-74. PubMed ID: 33010818
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
36. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
37. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
38. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
[TBL] [Abstract][Full Text] [Related]
40. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
